



Cue Biopharma to Present at BIO CEO & Investor Conference

February 7, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 7, 2018-- [Cue Biopharma](#)™, Inc., (NASDAQ: CUE) an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, announced today that it will be presenting at the BIO CEO & Investor Conference on Tuesday, February 13, 2018, at 1:30 pm ET (Odets Room), at the New York Marriott Marquis Hotel, NY. Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer, will provide an overview of the Company's technology platform and development strategy as well as updates on key programs and anticipated milestones. A live and archived version of the webcast will be available at <https://www.veracast.com/webcasts/bio/ceoinvestor2018/34223232419.cfm>. The presentation will also be archived for 30 days on the Investors section of the Company's website at www.cuebio.com.

About Cue Biopharma

Cue Biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. We design biologics to engage and modulate the activity of disease-associated T cells in the patient's body, with the goal of offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects.

We believe our biologics allow us to target antigen-specific T cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the Cue Biologics Platform. This flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost-efficiently than current industry standard timelines and costs.

Headquartered in Kendall Square, Cambridge, MA, we are led by an experienced management team and scientific and clinical advisory board (SAB/CAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

For more information, visit www.cuebio.com.

Forward-Looking Statements

All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our recently filed Registration Statement on Form S-1, which can be found on the SEC's website at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20180207005638/en/>

Source: Cue Biopharma, Inc.

Investor Contact:

Cue Biopharma
Kerri-Ann Millar, 617-949-2602

or

Media Contact:

Sam Brown Inc.
Cory Tromblee, 617-571-7220